A record of what Jefferies Analysis said publicly, with the source. Not advice.
“Upgraded Divi’s Laboratories to 'Buy', setting a target price of Rs 7,150, indicating a 19% upside from the closing price of Rs 6,027. This upgrade is driven by optimism surrounding its GLP-1 drug pipeline, which is expected to contribute significantly to future growth.”
Jefferies Analysis’s track record (trackable calls only): 153 graded calls · 95% CI 37–53%
How this call is judged
A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.
No entry price is stated, so the call starts at the first close after it was published.
Target ₹7,150, as stated.
Window: 12 months, the default when no time frame is stated.
The target ₹7,150 was reached on a close. Hit.
The grader’s working: R4 TARGET_CALL: entered ₹6190.5 on 2025-08-26 (next trading session's close); target ₹7150 reached at close ₹7188.5 on 2026-07-14. Window 365 days — rule H3: a target call whose quote states no time frame is given 12 months, the broker convention.
How it played out
How this is worked out- Time to target
- The target was reached on a close 215 trading sessions (322 calendar days) after the entry.
- Worst close against it
- The closing price went as far as 8.09% against the call before the target was reached, measured from the entry price. Closing prices only; an intraday dip is never counted.
From the entry the grade used, on closing prices. This is a record of one past call and is not advice.